An analysis of five clinical studies in which erlotinib or gefitinib was used as first-line treatment in NSCLC (stage IIIB or IV) revealed that the response rate was 67% in patients with sensitizing EGFR mutations (13). This evidence concerns the gene EGFR and non-small cell lung carcinoma.